Skip to main content

Table 7 Effect of treatment exposure for combined sulforaphane (SF) and placebo (PL) groups at 15 weeks and for SF-only group at 30 weeks

From: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder

Biomarker Intervention (exposure) Change
N F-statistic p value
Free reduced GSHa
 15 weeks 40 1.95 0.170
 30 weeks 22 0.75 0.485  
Total GSHa
 15 weeks 40 0.11 0.746
 30 weeks 22 0.06 0.946  
GSSGa
 15 weeks 40 0.15 0.701
 30 weeks 22 2.32 0.124  
Free GSH:GSSG
 15 weeks 40 3.90 0.055
 30 weeks 22 8.12 0.003  
Total GSH:GSSG
 15 weeks 40 1.32 0.258
 30 weeks 22 3.60 0.046  
  1. Bold signifies p < 0.05
  2. MANOVA test for repeated measures (compared to baseline at 0 weeks); analysis includes participants from the initial PL group while they were on SF at 22 and 30 weeks (their first 7 and 15 weeks of exposure)
  3. aNatural log transformed